0001628280-26-009046
SEC filingArtivion, Inc. reported total revenues of $441.3 million for fiscal year 2025, generating a gross margin of $284.2 million. Operating income was $33.7 million, which included a $7.0 million gain from the sale of non-financial assets. After accounting for $26.6 million in interest expense and $5.0 million in income tax expense, the company achieved net income of $9.8 million. Comprehensive income was $32.0 million, bolstered by $22.2 million in foreign currency translation adjustments. The company generated $39.9 million in operating cash flow but used $42.0 million in investing activities, primarily for capital expenditures and payments under Endospan agreements. The balance sheet shows total assets of $884.8 million, with $215.1 million in long-term debt and stockholders' equity of $448.2 million. The company ended the year with $64.9 million in cash and cash equivalents.
Artivion, Inc. reported fiscal year 2025 results with total revenues of $441.3 million. The company achieved gross margin of $284.2 million, representing a 64.4% gross margin rate. Operating income was $33.7 million, which included a $7.0 million gain from the sale of non-financial assets. After interest expense of $26.6 million and income tax expense of $5.0 million, net income was $9.8 million. Comprehensive income was $32.0 million, significantly higher than net income due to $22.2 million in foreign currency translation adjustments. Basic and diluted earnings per share were both $0. The company's weighted-average common shares outstanding were 45.3 million basic and 47.2 million diluted.
The filing does not provide segment breakdown or geographic mix data for revenue analysis. The total revenue figure of $441.3 million represents consolidated company performance without disclosure of specific revenue drivers, product categories, or geographic distribution. No information is provided about revenue growth rates compared to prior periods, market segments, or customer concentration. The absence of segment data limits detailed analysis of revenue composition and growth drivers.
Gross margin was $284.2 million on $441.3 million in revenue, resulting in a gross margin percentage of 64.4%. Total operating expenses were $257.5 million, consisting of $226.5 million in general, administrative, and marketing expenses and $31.0 million in research and development. Operating income of $33.7 million represents a 7.6% operating margin. The company's cost structure shows significant investment in general, administrative, and marketing functions, which accounted for 51.3% of total revenue. Research and development represented 7.0% of total revenue.
Operating activities generated $39.9 million in cash flow, driven by net income of $9.8 million and adjustments including $22.5 million in depreciation and amortization and $24.4 million in non-cash compensation. Investing activities used $42.0 million, primarily for $39.0 million in capital expenditures and $8.0 million in payments under Endospan agreements. Financing activities provided $11.3 million, mainly from $13.1 million in proceeds from exercise of stock options and issuance of common stock. The balance sheet shows total assets of $884.8 million, including $358.1 million in current assets and $254.1 million in goodwill. Total liabilities were $436.6 million, with $215.1 million in long-term debt. Stockholders' equity was $448.2 million, though this includes a retained deficit of -$51.5 million.
The filing does not provide management guidance, forward-looking statements, or specific strategic priorities for future periods. No information is disclosed about expected revenue growth, margin targets, capital expenditure plans, or debt reduction strategies. Risk factors and market outlook commentary are not included in the provided financial data sections. The absence of forward-looking information limits analysis of the company's strategic direction and expected performance in upcoming periods.